Our genetic data from ANGPTL7 homozygotes with up to a 69% risk reduction for all glaucoma and 80% risk reduction for primary open-angle glaucoma suggest that this is likely to be a safe and effective strategy for therapeutic intervention. This evidence concerns the gene ANGPTL7 and glaucoma.